Gaspard U
Service de Gynécologie, CHU du Sart Tilman-Université de Liège.
Rev Med Liege. 2003 Nov;58(11):709-12.
Evra is a transdermal patch releasing 20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin/day during one week. The circulating levels of steroids attained are of similar amplitude though steadier than after intake of an oral combined low-dose estrogen-progestin pill. The transdermal method is user-friendly and is abided by a high degree of acceptability, and a low level of skin irritability. Its contraceptive effectiveness is similar to that conferred by oral contraceptives except if the treated woman is over 90 kg, in which case Evra should not be prescribed. Cycle control is excellent and similar to that of triphasic pills. Adverse effects and tolerance are comparable to those described with low-dose oral contraceptives with a slight estrogen dominance. Lipid and glucose metabolism as well as coagulation are influenced in the same way. Gastrointestinal disturbances (nausea, vomiting) do not prevent the efficacy of the transdermal patch. Compliance with Evra is significantly higher than with oral combined contraceptives--a major point for an effective contraception. Accordingly, Evra constitutes an useful addition to the current array of contraceptive methods.
依伴依是一种透皮贴剂，每周释放20微克炔雌醇和150微克诺孕酯。所达到的甾体激素循环水平幅度相似，但比口服低剂量复方雌激素 - 孕激素 pill 后更稳定。透皮给药方法使用方便，接受度高，皮肤刺激性低。其避孕效果与口服避孕药相似，但治疗女性体重超过90公斤时除外，这种情况下不应开具依伴依。周期控制良好，与三相 pill 相似。不良反应和耐受性与低剂量口服避孕药相当，略有雌激素优势。脂质和葡萄糖代谢以及凝血受到同样影响。胃肠道紊乱（恶心、呕吐）不影响透皮贴剂的疗效。依伴依的依从性显著高于口服复方避孕药，这是有效避孕的一个要点。因此，依伴依是现有避孕方法中的一种有用补充。
